-
Mashup Score: 0Dapagliflozin improves endothelial function, microvascular reactivity in type 2 diabetes - 4 year(s) ago
Patients with diabetes experienced significant improvement in endothelial function and microvascular reactivity while taking daily dapagliflozin, according to research presented at the virtual Heart in Diabetes Conference.“Type 2 diabetes mellitus is a major risk factor for the development of cardiovascular disease and the development of atherosclerosis,” Oleksii Korzh, MD, DrMedSci,
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0AI can benefit care of patients with CVD, diabetes - 4 year(s) ago
Artificial intelligence has the ability to affect CV and diabetes care for both patients and clinicians, a presenter said. “The promise of artificial intelligence in health care is intriguing for controlling costs, increasing convenience, improving quality and improving outcomes,” Irving K. Loh, MD, FACC, FAHA, FCCP, FACP, chief medical officer and co-founder of Infermedica, internist
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: “The promise of [AI] in health care is intriguing for controlling costs, increasing convenience, improving quality and improving outcomes” @heartindiabetes #HID2020 #cardiotwitter @irvloh https://t.co/UalwD8S0XH
-
-
Mashup Score: 4Dapagliflozin improves endothelial function, microvascular reactivity in type 2 diabetes - 4 year(s) ago
Patients with diabetes experienced significant improvement in endothelial function and microvascular reactivity while taking daily dapagliflozin, according to research presented at the virtual Heart in Diabetes Conference.“Type 2 diabetes mellitus is a major risk factor for the development of cardiovascular disease and the development of atherosclerosis,” Oleksii Korzh, MD, DrMedSci,
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: “... the improvements in endothelial function from dapagliflozin treatment may contribute to its beneficial impact in [CV] morbidity and mortality,” Oleksii Korzh, MD, DrMedSci @heartindiabetes #HID2020 #cardiotwitter https://t.co/AQxmXosJRX
-
-
Mashup Score: 0AI can benefit care of patients with CVD, diabetes - 4 year(s) ago
Artificial intelligence has the ability to affect CV and diabetes care for both patients and clinicians, a presenter said. “The promise of artificial intelligence in health care is intriguing for controlling costs, increasing convenience, improving quality and improving outcomes,” Irving K. Loh, MD, FACC, FAHA, FCCP, FACP, chief medical officer and co-founder of Infermedica, internist
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: “The promise of [AI] in health care is intriguing for controlling costs, increasing convenience, improving quality and improving outcomes” @heartindiabetes #HID2020 #cardiotwitter @irvloh https://t.co/UalwD8Apz7
-
-
Mashup Score: 5Dapagliflozin improves endothelial function, microvascular reactivity in type 2 diabetes - 4 year(s) ago
Patients with diabetes experienced significant improvement in endothelial function and microvascular reactivity while taking daily dapagliflozin, according to research presented at the virtual Heart in Diabetes Conference.“Type 2 diabetes mellitus is a major risk factor for the development of cardiovascular disease and the development of atherosclerosis,” Oleksii Korzh, MD, DrMedSci,
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Patients with diabetes experienced significant improvement in endothelial function and microvascular reactivity while taking daily dapagliflozin @heartindiabetes #HID2020 #cardiotwitter https://t.co/AQxmXob90p
-
-
Mashup Score: 4AI can benefit care of patients with CVD, diabetes - 4 year(s) ago
Artificial intelligence has the ability to affect CV and diabetes care for both patients and clinicians, a presenter said. “The promise of artificial intelligence in health care is intriguing for controlling costs, increasing convenience, improving quality and improving outcomes,” Irving K. Loh, MD, FACC, FAHA, FCCP, FACP, chief medical officer and co-founder of Infermedica, internist
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Artificial intelligence has the ability to affect CV and diabetes care for both patients and clinicians @heartindiabetes #HID2020 #cardiotwitter @irvloh https://t.co/UalwD8S0XH
-
-
Mashup Score: 0Heart in Diabetes - 4 year(s) ago
The latest news from HiD, with physician perspective, interviews and clinician insight on cardiometabolic health.
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
Miss out on any of this week's @heartindiabetes coverage? Be sure to catch up on all of this weekend's biggest stories. #HID2020 @CardiologyToday https://t.co/JxOYRLWMmv
-
-
Mashup Score: 0
Glucose management remains important for adults with diabetes and advanced chronic kidney disease as a strategy to prevent or delay progression to dialysis, prevent cardiovascular events and improve quality of life, according to a speaker.“Why treat advanced CKD with glucose lowering? Isn’t it too late to achieve anything? I have this discussion with my nephrology colleagues quite
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: Glucose management plays a huge role in preventing cardiovascular events and improving quality of life for adults with #diabetes and advanced chronic kidney disease, says @heartindiabetes speaker #HID2020 https://t.co/Cg5nH3k9eC
-
-
Mashup Score: 0
Lifestyle or medical therapy in prediabetes to reduce later cardiovascular events in type 2 diabetes may seem wise, yet little evidence demonstrates such strategies make a difference, according to a speaker.“While logical, the evidence that preventing type 2 diabetes actually reduces CVD is scant,” Silvio E. Inzucchi, MD, professor of medicine at Yale University School of Medicine and
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: Lifestyle or medical therapy in prediabetes may not make a difference in reducing CV events later in life, according to a @heartindiabetes speaker #HID2020 https://t.co/wgEAKIJ8v9
-
-
Mashup Score: 0
Lifestyle or medical therapy in prediabetes to reduce later cardiovascular events in type 2 diabetes may seem wise, yet little evidence demonstrates such strategies make a difference, according to a speaker.“While logical, the evidence that preventing type 2 diabetes actually reduces CVD is scant,” Silvio E. Inzucchi, MD, professor of medicine at Yale University School of Medicine and
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: “While logical, the evidence that preventing type 2 #diabetes actually reduces CVD is scant. These are low-risk patients in most of these trials, and the follow-up is short.” @heartindiabetes #HID2020 https://t.co/wgEAKIJ8v9
-
ICYMI: “... the improvements in endothelial function from dapagliflozin treatment may contribute to its beneficial impact in [CV] morbidity and mortality,” Oleksii Korzh, MD, DrMedSci @heartindiabetes #HID2020 #cardiotwitter https://t.co/AQxmXob90p